Recently, scientists have made significant progress in the development of immunotherapeutics that correct aberrant, autoimmune responses. Yet, concerns about the safety, efficacy, and wide scale applicability continue to hinder use of contemporary, immunology-based strategies. There is a clear need for therapies that finely control molecular and cellular elements of the immune system. Biomaterial engineers have taken up this challenge to develop therapeutics with selective spatial and temporal control of immune cells. In this review, we introduce the immunology of autoimmune disorders, survey the current therapeutic strategies for autoimmune diseases, and highlight the ongoing research efforts to engineer the immune system using biomaterials, for positive therapeutic outcomes in treatment of autoimmune disorders.
Introduction to immune tolerance
The mammalian immune system is composed of a highly coordinated network of organs and cells that serve to rid the host of materials recognized as pathogens. 1, 2 Pathogens recognized by the immune system can include bacteria, viruses, and fungal cells. The immune system is divided into two sub-systems: innate immunity and adaptive immunity. The innate immune system encompasses the immediate, non-specific response. Innate immunity often involves physical barriers to pathogens (e.g. skin or mucosal epithelium), the activation of the complement system, local inflammation due to cytokine production, and the uptake of pathogens by antigen presenting cells (APCs) such as macrophages, dendritic cells (DCs), and neutrophils. Adaptive immunity, which is specific to an antigenic epitope, is associated with T and B cell activation, antibody production, and immunological memory. Adaptive immune cells also have the potential to generate an immune response against self-antigens, which can result in a loss of immune tolerance.
Immune tolerance describes an inability to mount an inflammatory response against a self-antigen. This inability is vital for maintenance of immune homeostasis and is accomplished by two mechanisms: central tolerance which occurs during the development of adaptive immune cells from stem cells, and peripheral tolerance, a continuous process of immune regulation throughout the host. 3 Central immune tolerance is defined by the negative selection of T and B cells that recognize self-antigens through their membrane bound receptors. 4 For the case of T cells this occurs in the thymus, and for B cells in the bone marrow. 4 Furthermore, peripheral tolerance describes induction of anergy, apoptosis, ignorance, or receptor editing outside the primary lymphoid organs. An anergic cell continually expresses unoccupied antigen receptors, yet is unresponsive to antigen stimulation. 5, 6 Whereas, apoptosis is a process in which cells undergo programmed cell death and can be induced through Fas/ Fas ligand interactions often found between T cells and thymic epithelial cells. 7 If adaptive lymphocytes are not exposed to their cognate antigen because it is in an immunologically privileged site (e.g. testis), they may become ignorant. Ignorant B cells that are self-reactive to sequestered antigen in inaccessible tissues are never stimulated and can eventually undergo apoptosis. However, their persistence can cause autoimmunity if antigen is released from an immunologically privileged site. 8 Central tolerance along with peripheral tolerance are essential for the immune system to identify, differentiate, and target self and non-self-antigens. self-antigens, inflicting damage to the host's own tissues. 9 In this scenario, self-reactive lymphocytes avoid central and peripheral tolerance-inducing mechanisms, and mediate an inflammatory response against self-antigens. Self-antigens recognized by autoreactive lymphocytes can range in nature and can be specific to organs or ubiquitous in the body. Examples of organ targets and the various roles of immune cells in autoimmune diseases are shown in Figure 1 .
Autoimmune disorders can cause tissue damage, abnormal growth, and changes in organ function. Often, when tissue is destroyed, more self-antigen is released into the periphery leading to exacerbation of the disease. This is especially the case when the antigen is hidden in an immunologically privileged site, such as the eye. 8 
T helper Type 1 (T h1 ) cells
Autoimmunity can either be T cell or B cell-mediated. The primary orchestrator of T cell-mediated autoimmunity can be T helper Type 1 (T h1 ), T h2 , or Interleukin (IL)-17 secreting T h17 cells. The T h1 response is dominant in autoimmune diseases such as type I diabetes and rheumatoid arthritis, and leads to the destruction of nerve axons in multiple sclerosis. 10 T h1 CD4þ cells secrete pro-inflammatory cytokines such as IL-2, interferon gamma (IFN-y), tumor necrosis factor alpha (TNF-a), and granulocyte-macrophage colony-stimulating factor (GMCSF), efficiently activating macrophage effector functions. 11 
T helper Type 17 (T h17 ) cells
Another effector cell in autoimmunity, T h17 cells were first identified in 2005 and are the cellular source of IL-17. 12, 13 T h17 cells and tolerance-inducing regulatory T cells (T regs ) counteract each other in the development of autoimmune and inflammatory diseases. Accumulation of T h17 cells was the first observation to support the notion that IL-17 contributes to the pathogenesis of experimental autoimmune encephalomyelitis (EAE). 14 Additionally, mice deficient in IL-17 are resistant to the onset of collagen-induced arthritis. 15 In humans, T h17 cells and their cytokines are also associated with several autoimmune and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, and inflammatory bowel disease 12, 16 (See Figure 1 ).
T helper Type 2 (T h2 ) cells/B cells
T helper Type 2/B cell-mediated autoimmune responses are generally characterized by the production of IgG and IgE antibodies against a self-antigen by stimulated B cells. 11, 17 Antibodies against self-antigens can create a myriad of systemic problems. Cell receptor autoantibodies can bind to signaling receptors and cause a continual stimulation of the receptor, or block stimulation of the receptor altogether. An example of an autoimmune disease that involves a receptor blocking autoantibody is myasthenia gravis, in which B cells produce autoantibodies against acetylcholine receptors in the synaptic junction, blocking receptor activation by acetylcholine released from the synaptic terminal of Figure 1 The general contributions of lymphocytes (B cell, T cells and dendritic cells) to the pathogenesis of autoimmune disorders, which affect multiple organs throughout the body. the neuron. 18 In Grave's disease, the scenario is slightly different, thyroid-stimulating immunoglobulins recognize and bind to the thyrotropin receptor (TSH receptor) which stimulates the secretion of thyroxine and triiodothyronine. The result is high levels of circulating thyroid hormones and hyperthyroidism. 19 It should be noted that T cell subsets typically work in concert with other T cell subsets and immune cell types (e.g. B cells) in the development of autoimmune diseases (See Figure 1 ). 20 For instance, in type I diabetes, it is evident that T h1 and T h2 -derived cytokines cooperate to drive b-islet-cell destruction. 20 At its core, the development of autoimmunity is due to a breakdown in the immune self-recognition. It has been reported that this breakdown is catalyzed by different factors including: genetic abnormalities in the human leukocyte antigen (HLA) regions, newly exposed antigens in the body, infections that overcome tolerance, pathogenic molecular mimicry, development of altered self-antigens due to binding of molecules to cell surfaces, or hormone imbalances. 9, 21, 22 Current strategies for immunotherapy of autoimmune diseases
Over the last quarter century, immunotherapy has come to the forefront of basic and clinical research as a leading candidate for the cure of a broad array of immune conditions. In the context of autoimmune diseases, immunotherapy is defined as a strategy that either interrupts immune dysregulation, or induces specific immune tolerance to self-antigens. This form of immunologic intervention was first launched in the early 1980s, after clinicians recognized that polyclonal IgG immunoglobulin (IVIG) improved autoimmune thrombocytopenia in patients being treated for immunodeficiency. 23 Today, autoimmune disease treatment accounts for greater than 70% of IVIG clinical use in the US. In addition to IVIG, a host of immuno-modulatory agents and strategies have been developed to curb the increasingly prevalent epidemic of autoimmune and autoinflammatory disease. Coinciding with breakthroughs in molecular biology, immunologists have created novel immunotherapeutic approaches that can be broadly categorized as non-specific molecular immuno-modulation (e.g. IL-1 agonist), effector cell depletion (e.g. anti-thymocyte globulin [ATG]), and regulatory cell adoptive transfer (e.g. regulatory T cell therapy).
Non-specific molecular immuno-modulation
Non-specific immuno-modulation typically involves the administration of a single agent, or combination of factors with capacity to block auto-inflammatory pathways, induce regulatory cascades, or sequester soluble mediators of autoimmunity. Table 1 describes a number of molecular immuno-modulators that are currently in clinical use. These drugs are typically classified as disease-modifying agents (DMAs), or biological response modifiers (BRMs) based on their ability to modify inflammatory elements of the disease. Moreover, DMAs tend to be non-biologic drugs with wide-ranging effects on immune and other cell types. However, administration of this group of drugs can have adverse side effects, which inspired research to identify and develop immunotherapeutics that more selectively halt the inflammatory mechanisms of autoimmune disease. Pioneered in the early 1980s, the next generation of immunotherapeutics was predominantly BRMs. These biologics were bioengineered recombinant proteins and monoclonal antibody products designed to suppress inflammatory responses to self-antigen by targeting critical mediators, such as cytokine receptors (e.g. IL-2 receptor alpha subunit [IL-2Ra; CD25]). IL-2, a key cytokine for the differentiation, survival and functionality of regulatory T cells, was one of the first bioengineered proteins for immunotherapy. Pleiotropic in nature, IL-2 can be both anti-inflammatory and pro-inflammatory, and was first used at high doses to treat cancer. 24 Ironically, research on IL-2 as a cancer therapeutic lead to the discovery that at very low doses, it could bolster the regulatory activity of T regs . 25, 26 Clinical trials are currently underway to establish whether low-dose IL-2 could restore the T reg / effector T cell (T eff ) ratio in diseased patients and, thereby be an effective therapeutic for type 1 diabetes and other autoimmune conditions (ClinicalTrials.gov Identifier: NCT02265809). Other examples of BRMs include cytokine inhibitors, such as Adalimumab and Rilonacept, that bind disease-propagating cytokines. 27, 28 Though sales of cytokine inhibitors are now a considerable percentage of the immunotherapeutic market, this class of drugs is not without its share of adverse effects. 29 Reactions at the site of injection are the most common side effects, but can be managed via pretreatment with antihistamines and steroids. However, other more serious reactions, though infrequent, have occurred with the use of cytokine inhibitors including anaphylaxis, thrombocytopenia, neutropenia, heart disease, and induction of autoimmune disorders. 27 Another major side effect is risk of serious infections, particularly bronchial and pulmonary. 30 
Effector cell depletion
It has long been recognized that various subsets of T-and B cells play an important role in the propagation of autoimmune disease and transplant rejection. As such, agents directed at inhibition of these effector cells have been developed. Most notably, antibodies that directly eliminate or suppress the functions of effector immune cells have been used as therapeutic agents for an array of autoimmune disorders. For instance, Alemtuzumab (Lemtrada Õ ), a monoclonal antibody against CD52, is currently used for treatment of multiple sclerosis and organ rejection. CD52 is a ubiquitous receptor found on the surface of lymphocytes and monocytes, but, not on their respective progenitors. 31 Treatment with Alemtuzumab, results in rapid depletion of mature lymphocytes and significant lymphopenia. 32 Unaffected lymphoid progenitor cells then proliferate and replace lymphocytes lost to this treatment. This immune cell reconstitution is dominated by the emergence of regulatory T cells that suppress autoimmune responses. 32 Other monoclonal antibody therapies, such as Teplizumab and Rituximab aim at deleting autoreactive T cells or B cells and increasing the presence of T regs . 33, 34 Predictably, immune cell ablation is often accompanied by severe side effects including risk of infection, induction of carcinogenesis, autoantibody formation, cytopenia, and acute demyelinating complications. Milder effects such as infusion/injection site reactions and abnormalities in lipid profiles are also frequently observed in patients treated with immune cell ablation therapies. 27 
Regulatory cell adoptive augmentation
The development of immunotherapeutics that prompt specific immune responses while minimizing harmful complications is currently a priority for the clinical community. These design criteria, along with a new emphasis on developing patient-centered therapeutic regimens, have led to the development of cell-based therapies for treatment of autoimmune disorders.
There is now an overwhelming body of work that supports the notion that regulatory T cells are critical for controlling autoimmunity and inducing tolerance. Regulatory T cells suppress the activities of self-destructive effector immune cells via mechanisms involving cell-cell contact as well as soluble mediators. 35 Moreover, work by Brusko et al. and others demonstrated that the frequency of functional T regs is significantly reduced in multiple autoimmune disorders. 36, 37 Thus, it is not surprising that the researchers have focused on developing T regs as a cell therapy product for the treatment of autoimmune disease. Efforts to translate the success of T reg infusion therapy in animal models of autoimmune disease to humans are being led by the Jeffrey Bluestone group. They first reported that ex vivo-expanded T regs maintained a regulatory profile (high levels of CD25, CD62L, FoxP3 and CTLA-4) and suppressed proliferation of effector T cells in vitro. 38 Further, adoptive transfer of antigen-specific BDC2.5 T regs into new onset, diabetic NOD mice reversed hyperglycemia at a rate of 60%. 38 Clinically, investigators have established that polyclonal T reg therapy is effective for the prevention of graft-versushost disease (GVHD) 39 and improves b cell function in children with type 1 diabetes. 40 There are currently 12 clinical trials in progress on the safety and efficacy of polyclonal T reg therapy. However, serious concerns on the feasibility of this approach still remain. Especially, given that large-scale production of antigen-specific T regs for autoimmune disease therapy is difficult because of their low bioavailability and lack of stability during expansion.
Another viable cell therapeutic approach that is currently under investigation is dendritic cell-based therapy. Tolerogenic DCs (tDCs) can promote central and peripheral tolerance via a number of mechanisms including T cell anergy, T reg generation, and effector T cell deletion. 41, 42 These tDCs are now under intense investigation for use as ''live vaccines'' in antigen-specific immunotherapy and transplantation medicine. In this personalized form of medicine, patient-derived DCs are manipulated ex vivo to a tolerogenic phenotype and then re-infused into the patient as a cellular drug. 42, 43 A phase I clinical trial in type 1 diabetics revealed that tDC vaccination is well tolerable and does not induce autoantibody formation. Additionally, beneficial immune responses observed were increased plasma levels of IL-4 and IL-10, and increased frequency of suppressive B220þCD11c-B cells. 44 Cell-based therapies hold great promise for the generation of antigen-specific tolerance in patients with selfdestructive diseases, without the adverse effects that commonly accompany other immunotherapeutic techniques. However, issues such as consistency and stability of immunophenotype, and exceedingly high manufacturing costs may restrict the broad utilization of this therapeutic approach. 45 Other immunotherapeutic strategies for autoimmunity that are receiving considerable attention include postcytokine receptor signaling interference and immune system regeneration using stem cells. These approaches were excellently reviewed by Patterson et al., 46 and Munir et al. 47 respectively.
Biomaterial-based tolerogenic immunotherapy
Traditionally, the host immune system has been viewed with contempt by biomaterial scientists, due to its reactions, including the foreign body response (FBR), that typically degrade and destroy the functionality of implanted materials and/or devices (e.g. insulin pump). However, there is now recognition that biomaterials can be engineered to manipulate the immune system for therapeutic and diagnostic applications. Biomaterial surface chemistry, surface topography, microscale architecture, and other physiochemical properties have been controlled to either mitigate or propagate immune responses. Herein, we focus on strategies that researchers have employed to dampen selfgenerated immunity with special emphasis on particulate engineering, tolerogenic drug delivery, and lymph node conditioning.
Particulate engineering for tolerogenic outcomes
With new insights into the immunobiology of APCs, there is now a concentrated effort to develop particulate vehicles for the delivery of antigen and adjuvant. Particulate uptake, antigen processing, antigen presentation, and T cell activation are critical immunological processes that are all innate to APCs, particularly DCs. Additionally, particulate delivery systems protect their cargo from degradation and rapid clearance. 45 Moreover, particle characteristics can influence these processes and therefore direct immunological outcomes.
One particulate parameter that has been manipulated to influence APC functionality and downstream immune responses is size. Particulate vaccines typically vary from 10 nm to 500 mm in diameter, which is similar to the size range of microbial organisms, against which APCs have evolved to purge from the host. 48 Particles below the 500 nm size range can be taken up by endocytosis, a process common to most cells. On the other hand, microparticles (MPs) in the 0.5-7 mm size are readily eaten by APCs through a unique process called phagocytosis. 48 Internalization of particulates by phagocytosis is critical for immune modulation, as following uptake particles enter the phagosome which promotes antigen cross-presentation. 49 Cross-presentation by APCs is the phenomenon where exogenously derived (located outside the cell) antigen is displayed on MHC class I molecules to CD8þ T cells. This process may be important for enlisting all the facets of the adaptive immune system and, mounting effective tolerogenicity. 41 Contrastingly, antigen internalized via endocytosis is poorly cross-presented. 50 Other physical parameters that should be considered in designing particulate vaccines for tolerogenic applications include shape, surface chemistry, and hydrophobicity. These factors have been shown to significantly alter interactions with APCs, as well as, influence their phenotype. 48, 51 For example, Champion et al. 52 demonstrated that worm-like particles with very high aspect ratios (>20) exhibits significantly lower phagocytosis by macrophages in comparison to spherical particles of equal volume. With respect to particle surface chemistry, various groups have reported that the surface charge of particles significantly influenced the maturation status and cytokine secretion of engulfing DCs. Jilek et al. 53 showed that exposure of human-derived DCs to anionic poly (lactic-co-glycolic acid) (PLGA) MPs significantly upregulated expression of co-stimulatory markers (CD83 and CD86) and increased secretion of pro-inflammatory cytokines -IL-12 and TNF-a. The hydrophobicity factor, which is interrelated with surface chemistry, is another design consideration for particulate vaccines. Plasma proteins (e.g. immunoglobulin, complement) quickly adsorb onto the surface of hydrophobic particles in the body, thereby earmarking them for clearance by the reticuloendothelial system. 54 Evidently, passive adsorption of proteins onto the surface of particulate vaccines could reduce their in vivo half-life and diminish their therapeutic or diagnostic purposes. Addition of polyethylene glycol (PEG) is a popular approach adopted by researchers to increase the hydrophilicity of particles and thus reduce passive adsorption of plasma proteins. 55, 56 PEGylation of particulates has been extensively studied and has been shown to effectively reduce uptake by phagocytic cells in vitro, extend circulation half-life in vivo, and decrease the accumulation of nanoparticles (NPs) in the liver. 57, 58 Interestingly, hydrophilicity may be an important factor for pushing suppression of autoimmune reactions. A report by Liu et al. 59 suggested that increased hydrophobicity of PLGA particles promotes particulate uptake, and expression of positively stimulatory surfaces molecules in bone marrow-derived DCs.
The surface chemistry can also be exploited for active targeting of biomaterial-based particulates to specific immune cells. Active targeting of particulates may improve cargo delivery, reduce harmful off-target effects, and initiate immune receptor-signaling pathways. 2 Particulate active targeting can be accomplished by surface absorption or ligation of ligands with high affinity for specific molecules found on the surface of immune cells. In the context of tolerogenic applications, it is vital that engagement of these surface receptors does not stimulate inflammatory pathways. To this end, work done by the Keselowsky 60 group showed that PLGA microspheres with surfaceimmobilized ligands (DEC205 mAb, CD11c mAb and P-D2 peptide) enhanced particulate uptake by DCs in vitro and in vivo without inducing DC maturation. Santamaria and co-workers 61 further exploited surface modification of biomaterial particulates in designing a novel, artificial antigen-presenting cell system for remission of autoimmune disorders.
Delivery of tolerance-inducing agents
A prominent, biomaterial-based strategy for manipulation of the immune system is controlled release of immunomodulatory agents from particulates. Polymeric particles, liposomes, and hydrogels have been used to deliver an array of immuno-modulatory agents, including antigen, 62 nucleic acids, 63 cytokines, 64 and pharmacological drugs, 65 for immunotherapy of auto-inflammatory diseases. As described above, current therapeutic strategies for selfgenerated inflammation are broadly based on non-specific, molecular or cellular ablation and regulatory immune cell augmentation and are typically accompanied by adverse side effects (e.g. cytokine-release syndrome) or fail to meet required safety standards for biotechnology products. Biomaterial-based particulate systems offer direct delivery of immuno-modulators to specific immune cells for induction of long-term tolerance or immuno-suppression.
Most classically, poly (lactic-co-glycolic acid) (PLGA; or variants thereof) particulates, ranging from nano-to microscale in size, have been used as immunotherapeutic, delivery systems. This biopolymer can be tailored by varying lactic to glycolic acid composition and molecular weight. Favorable qualities of PLGA include biocompatibility, biodegradability, and control of physiochemical properties, i.e. size, shape, hydrophobicity, loading, and release kinetics of a wide range of biomolecules. Additionally, reports have indicated that certain formulations of PLGA may inhibit inflammatory immune reactions. 66, 67 However, others have contradicted this notion and suggested that PLGA is intrinsically immunogenic. 68 Recently, Phillips and his coworkers. demonstrated that PLGA microspheres loaded with anti-sense oligonucleotides, for co-stimulatory molecules (CD40, CD80, and CD86), passively targeted DCs and manipulated their immuno-regulatory function. This MP system protected NOD mice from T1D by suppressing the expression of these positively stimulatory molecules in APCs that intercepted microspheres. Similarly, Lewis et al. 67 showed that a combinatorial MP system can modify immune cell phenotype and prevent autoimmune diabetes in NOD mice, by delivering a payload of immunomodulatory agents. They developed a unique system consisting of two classes of PLGA MPs (based on size)phagocytosable MPs delivering antigen (denatured insulin) and tolerizing drug (vitamin D3) to intracellular receptors, and unphagocytosable MPs to extracellularly deliver DC recruitment and immuno-suppressive biological factors (GM-CSF, TGF-b1). In pre-diabetic NOD mice, this particulate therapy prevented the development of auto-reactive diabetes, though it was unclear what mechanisms are involved in this observed protection. 67 This same group of researchers formulated a combination hydrogel-microparticle vaccine, which included an inflammatory adjuvant, for treatment of type 1 diabetes. They found that a vaccine delivery system, comprising a peptide-based hydrogel loaded with GM-CSF, CpG (unmethylated linear DNA sequence of cytosine nucleotide phosphate-linked to guanine nucleotide), and PLGA MPs encapsulating denatured insulin, significantly prevented autoimmune diabetes onset in pre-diabetic NOD mice. Mechanistically, they postulated that CpG promoted the secretion of the antiinflammatory cytokine IL-10 from hydrogel-infiltrating DCs, which also captured MP-encapsulated self-antigen. 69 Immuno-engineers have also utilized ''nanogel'' particulates for effective delivery of small molecule drugs to immune cells as a therapeutic measure for systemic lupus erythematosus. Systemic lupus erythematosus is a multiorgan, autoimmune disorder where dysregulated activation of immune cell subsets leads to auto-antibody accumulation in various tissues, which is followed by tissue-destructive inflammation. 70 Following intravenous administration, nano-sized particles amass in several tissues, including those commonly affected in SLE (e.g. lungs, liver). Thus, it is rational to use NPs for co-localization of DMAs with self-reactive, cellular mediators of lupus. Look et al. 71 adopted this approach and established that mycophenolic acid (MPA)-loaded nanogels effectively treated murine lupus. 71 Existing limitations to tolerogenic MP delivery formulations include the bulk production of particulates, as the large-scale manufacture is often inefficient, difficult, and costly. Additionally, the bioactivity of the encapsulated and surface-immobilized agents can be significantly reduced due to harsh environments these factors may be exposed to during the particle generation process. 45 
Tolerogenic conditioning of lymph nodes
An emerging strategy for autoimmune disease immunotherapy focuses on engineered particulates that release tolerizing drug payloads into secondary lymphoid organs, such as lymph nodes (LNs). The LN is considered the ''command center'' of the immune system, due to the high density of T and B cells housed within these anatomic structures. Moreover, it is where naïve T cells and B cells are primed by APCs such as DCs to initiate adaptive immunity. 72 Additionally, B cells can capture antigen directly in the LN and produce associated antibodies. 73 Typically, vaccines are administered via intramuscular or subcutaneous routes, and are then translocated to the LN via phagocytic cells or lymphatic conduits. Ostensibly, there is significant loss and degradation of antigen and adjuvant during this process, leading to ineffective immunity and other undesirable offtarget effects. Precise delivery of vaccine components to the LN promises to boost desired immune responses. To achieve this goal, researchers have applied principles of biomaterial particulate engineering. For example, the research groups of Jeffrey Hubbell and Melody Swartz engineered poly (propylene sulfide) nanoparticles (PPS NPs) for conveying vaccine antigens to LN-resident DCs. Their studies indicated that PPS NPs were passively trafficked to draining lymph nodes via interstitial fluid flow through the lymphatics following subcutaneous injection. Moreover, antigen conjugated to these 20 nm PPS NPs elicited levels of cellular and humoral immunity comparable a co-injection of antigen and lipopolysaccharide (LPS), a powerful immunogenic adjuvant. 74, 75 Although these studies focused on generating immunity, it is reasonable to suggest that this approach with careful selection of adjuvant(s) could induce tolerance directly at the LN. Another direct strategy that may yield positive therapeutic outcomes in an autoimmune setting is intra-lymph nodal (i.LN) injection of controlled release particulates. The Jewell research group showed that i.LN immunization with slow releaseformulated adjuvants is a useful approach to prolong and boost prophylactic vaccines while reducing harmful offtarget and systemic effects. 76 
Conclusions and outlook
The incidence of autoimmune diseases continues to rise every year, with current remedies either therapeutically inadequate, or accompanied by adverse effects that negate the benefits of their administration. Biomaterial-based immune-engineering holds great potential for rational design of effective and safe immunotherapeutics for autoimmune disorders. Biomaterials can offer a platform for precise spatial and temporal control of immune systemimmunotherapeutic interactions. Additionally, biomaterials with inherent immune-modulatory properties are currently under investigation for selective regulation of autoimmune reactions. Although this review focused on the application of biomaterials for immunotherapy of autoimmune disease, biomaterial strategies can also be helpful for building models to better understand the pathogenesis of autoimmune disorders. However, the promise of biomaterialbased modulation of the immune system will never come to fruition if certain challenges are not addressed. Most notably, manufacturability (cost and scale-up of clinical grade materials) of these technologies and elucidation of the intrinsic immunogenicity of biomaterial products in vivo are significant hurdles that must be overcome moving forward to full translation.
